1. Home
  2. NSTS vs RNTX Comparison

NSTS vs RNTX Comparison

Compare NSTS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NSTS Bancorp Inc.

NSTS

NSTS Bancorp Inc.

HOLD

Current Price

$14.06

Market Cap

66.6M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$0.71

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NSTS
RNTX
Founded
1921
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.6M
65.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
NSTS
RNTX
Price
$14.06
$0.71
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
11.9K
489.7K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.16
EPS
N/A
N/A
Revenue
$252,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.73
$0.69
52 Week High
$14.19
$2.18

Technical Indicators

Market Signals
Indicator
NSTS
RNTX
Relative Strength Index (RSI) 68.06 41.43
Support Level $13.70 $0.71
Resistance Level N/A $0.88
Average True Range (ATR) 0.06 0.06
MACD 0.00 -0.00
Stochastic Oscillator 50.00 7.38

Price Performance

Historical Comparison
NSTS
RNTX

About NSTS NSTS Bancorp Inc.

NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: